Investment Thesis
Elanco exhibits critical operational distress with negative free cash flow of -$38M and interest coverage of 0.5x, indicating inability to service debt from operations despite $1.4B revenue. The 169% EPS decline, 0.9% ROE, and 6.3% operating margin reveal structural profitability issues that cannot be sustained; while gross margins of 57.3% show pricing power, operational expenses and working capital management appear severely impaired.
Strengths
- Healthy gross margin of 57.3% demonstrates pricing power and cost control
- Positive revenue growth of 6.2% YoY in stable pharmaceutical sector
- Moderate leverage with 0.57x debt-to-equity ratio provides some refinancing flexibility
- Adequate short-term liquidity with 2.16x current ratio and $428M cash position
Risks
- Negative free cash flow of -$38M on $1.4B revenue indicates severe working capital deterioration and unsustainable cash burn
- Interest coverage of 0.5x means operating income cannot service debt; existential solvency risk if debt restructuring required
- EPS collapsed 169% YoY amid only $57M net income, signaling fundamental earnings quality collapse
- Minimal returns with ROE of 0.9% and ROA of 0.4%; operating margin of 6.3% is critically low for pharmaceutical company
Key Metrics to Watch
- Free cash flow path to positive territory and operating cash flow improvement
- Operating margin expansion toward 12-15% pharma industry baseline
- Interest coverage ratio and debt reduction plan to achieve minimum 1.5x coverage
- EPS stabilization and whether recent deterioration represents cyclical or structural decline
Financial Metrics
Revenue
1.4B
Net Income
57.0M
EPS (Diluted)
$0.11
Free Cash Flow
-38.0M
Total Assets
13.2B
Cash
428.0M
Profitability Ratios
Gross Margin
57.3%
Operating Margin
6.3%
Net Margin
4.2%
ROE
0.9%
ROA
0.4%
FCF Margin
-2.8%
Balance Sheet & Liquidity
Current Ratio
2.16x
Quick Ratio
1.12x
Debt/Equity
0.57x
Debt/Assets
50.8%
Interest Coverage
0.46x
Long-term Debt
3.7B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T10:07:33.000339 |
Data as of: 2026-03-31 |
Powered by Claude AI